BANOOK ACQUIRES FLUIDDA, STRENGTHENING ITS GLOBAL LEADERSHIP IN RESPIRATORY CLINICAL TRIALSERVICES
Banook broadens its expertise beyond cardiac and imaging endpoints into
respiratory medicine, one of the fastest-growing clinical research domains
- Fluidda’s Functional Respiratory Imaging (FRI) platform enhances Banook’s
data analytics and imaging capabilities for complex global trials - The respiratory clinical trial services market is valued at over $3 billion and
expected to grow at high single digits - The combined group strengthens its presence across Europe, North America,
and Asia-Pacific, offering integrated endpoint management and imaging
services
Nancy (France), Kontich (Belgium), 13 November, 2025 – Banook, a leading global
provider of centralized cardiac safety, central imaging and clinical endpoint
management services, today announced the acquisition of Fluidda, a pioneer in
respiratory imaging and Functional Respiratory Imaging (FRI) technologies. The
acquisition marks a significant milestone in Banook’s strategy to diversify and expand
into respiratory clinical research and advanced imaging analytics.
Founded in Belgium, Fluidda is recognized globally for its expertise in computational
fluid dynamics and quantitative CT-based imaging to assess lung structure and
function. Its proprietary Functional Respiratory Imaging (FRI) platform is widely used
to optimize drug development and improve patient outcomes in chronic respiratory
diseases such as asthma, COPD, interstitial lung disease (ILD), and pulmonary
hypertension (PH).
By integrating Fluidda’s cutting-edge imaging capabilities with Banook’s operational
excellence in endpoint management and global clinical trial delivery, the combined
organization will offer an unmatched portfolio of scientific, imaging, and data-driven
services across respiratory and cardiovascular therapeutic areas.
Categorised in: Miscellaneous / November 13, 2025 8:00 am /